PARK INNOVARE

News

Dr. Fabia Gozzo: an exceptional, creative, inventive, and innovative woman and entrepreneur

In a couple of weeks, London will welcome some of the world’s most innovative women from all sectors and backgrounds. The 21st Global Women Inventors,...

More details More details

Novel Accelerators for Electron Diffraction workshop at PARK INNOVAARE

Understanding how matter creates life requires observing living cells with atomic detail. There are many ways to do so, but one possibility has been gaining...

More details

WE ARE HIRING!

PARK INNIVAARE is an innovation park next to the Paul Scherrer Institute PSI. It offers academic spin-offs, innovative start-ups, SMEs and big companies,...

More details

A platform to discuss high-level topics with the pharmaceutical industry

Novartis (Switzerland) and Alphora (Canada) joined the case study program conducted as part of the Second Annual Spring Pharmaceutical Synchrotron X-Ray...

More details

“Winning the Swiss BIC has helped us broaden our network”

Nowadays, cities face the ever-rising challenge of ensuring security, be it a low crime rate, reliable infrastructure, or safe traffic. At the same time,...

More details

Securaxis is the winner of the "Swiss BIC of CERN Competition"

Nowadays, cities face the ever-rising challenge of ensuring security, be it a low crime rate, reliable infrastructure, or safe traffic. At the same time,...

More details

PARTICLE ACCELERATOR TOOLBOX PART I: BUILDING ACCELERATOR

Particle accelerators are mighty complex machines. It takes decades and hundreds of highly-specialized experts to build and operate one. It is not surprising...

More details

BIC of CERN Technologies calls for innovative ideas leveraging accelerator technologies

As of today, start-ups and spin-offs, as well as small high-tech companies, younger than two years, can apply to become the next Business Incubation Centre...

More details

InterAx partners with Lundbeck to identify better pharmaceutical compounds

InterAx Biotech AG, a spin-off of the Paul Scherrer Institute PSI and ETH Zurich, based at PARK INNOVAARE, is building a proprietary systems biology platform...

More details

Excelsus invites pharma companies to explore for free the possibilities of synchrotron X-ray powder diffraction

The second annual Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction (SPS-XRPD-2) Workshop, organized together with the 16th Pharmaceutical Powder...

More details

InterAx raises CHF 3 Mio for the commercialization of its systems biology platform

InterAx Biotech AG is a spin off from the ETH Zürich and Paul Scherrer Institute (PSI). The company assists GPCR drug candidate design and selection by...

More details

Two well-known techniques + new application field = breakthrough of the year

This fall, Dr. Tim Grüne from the Paul Scherrer Institute (PSI) together with Crystallise! AG published the results of their joint project, presenting...

More details
1 2 3 4 5 6 7 8 9